Last reviewed · How we verify
GBS glycoconjugate vaccine
GBS glycoconjugate vaccine is a Biologic drug developed by Novartis Vaccines. It is currently in Phase 1 development.
At a glance
| Generic name | GBS glycoconjugate vaccine |
|---|---|
| Sponsor | Novartis Vaccines |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine (PHASE1)
- A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine (PHASE1)
- Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings (PHASE2)
- A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age (PHASE1)
- A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GBS glycoconjugate vaccine CI brief — competitive landscape report
- GBS glycoconjugate vaccine updates RSS · CI watch RSS
- Novartis Vaccines portfolio CI
Frequently asked questions about GBS glycoconjugate vaccine
What is GBS glycoconjugate vaccine?
GBS glycoconjugate vaccine is a Biologic drug developed by Novartis Vaccines.
Who makes GBS glycoconjugate vaccine?
GBS glycoconjugate vaccine is developed by Novartis Vaccines (see full Novartis Vaccines pipeline at /company/novartis-vaccines).
What development phase is GBS glycoconjugate vaccine in?
GBS glycoconjugate vaccine is in Phase 1.
Related
- Manufacturer: Novartis Vaccines — full pipeline
- Compare: GBS glycoconjugate vaccine vs similar drugs
- Pricing: GBS glycoconjugate vaccine cost, discount & access